Association of excessive daytime sleepiness with longitudinal β-Amyloid accumulation in elderly persons without dementia

JAMA Neurology

Volumn 75, Issue 6, 2018, Pages 672-680

  Carvalho, Diego Z ^a   St Louis, Erik K ^a   Knopman, David S ^a   Boeve, Bradley F ^a   Lowe, Val J ^a   Roberts, Rosebud O ^a   Mielke, Michelle M ^a   Przybelski, Scott A ^a   Machulda, Mary M ^a   Petersen, Ronald C ^a   Jack, Clifford R ^a   Vemuri, Prashanthi ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E;

AGE; AGED; ALLELE; ALZHEIMER DISEASE; ANTERIOR CINGULATE; ARTICLE; BRAIN REGION; COMORBIDITY; CONTROLLED STUDY; DAYTIME SOMNOLENCE; DEMENTIA; DEPRESSION; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE MARKER; EDUCATION; EPWORTH SLEEPINESS SCALE; FEMALE; GENDER; HIGH RISK POPULATION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; LONGITUDINAL STUDY; MALE; MINNESOTA; OBESITY; PARIETAL CORTEX; PHYSICAL ACTIVITY; POPULATION RESEARCH; POSITRON EMISSION TOMOGRAPHY; POSTERIOR CINGULATE; PRECUNEUS; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIOLOGICAL PARAMETERS; RESPIRATORY TRACT DISEASE; SLEEP TIME; VERY ELDERLY; DIAGNOSTIC IMAGING; FOLLOW UP; METABOLISM; SOMNOLENCE;

AGED; AGED, 80 AND OVER; AMYLOID BETA-PEPTIDES; DEMENTIA; DISORDERS OF EXCESSIVE SOMNOLENCE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LONGITUDINAL STUDIES; MALE; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; SLEEPINESS;

EID: 85046108702     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaneurol.2018.0049     Document Type: Article

References (93)

1. American Academy of Sleep Medicine. The International Classification of Sleep Disorders: Diagnostic and Coding Manual. 2nd ed.Westchester, IL: American Academy of Sleep Medicine; 2005.
2. Young TB. Epidemiology of daytime sleepiness: definitions, symptomatology, and prevalence. J Clin Psychiatry. 2004;65(suppl 16):12-16.
3. Hayley AC, Williams LJ, Kennedy GA, Berk M, Brennan SL, Pasco JA. Prevalence of excessive daytime sleepiness in a sample of the Australian adult population. Sleep Med. 2014;15(3):348-354.
4. Bixler EO, Vgontzas AN, Lin HM, Calhoun SL, Vela-BuenoA, KalesA.Excessivedaytime sleepiness in ageneralpopulationsample:theroleofsleepapnea, age, obesity, diabetes, and depression. J Clin Endocrinol Metab. 2005;90(8):4510-4515.
5. GooneratneNS, WeaverTE, CaterJR, etal.Functional outcomesofexcessivedaytimesleepinessinolderadults. J AmGeriatr Soc. 2003;51(5):642-649.
6. FoleyD, MonjanA, MasakiK, etal.Daytimesleepiness is associated with 3-year incident dementia and cognitivedeclineinolderJapanese-Americanmen.JAm Geriatr Soc. 2001;49(12):1628-1632.
7. Jaussent I, Bouyer J, Ancelin ML, et al. Excessive sleepiness is predictive of cognitive decline in the elderly. Sleep. 2012;35(9):1201-1207.
8. TsapanouA, GuY, ManlyJ, et al.Daytime sleepiness and sleep inadequacy as risk factors for dementia. Dement Geriatr Cogn Dis Extra. 2015;5(2):286-295.
9. Elwood PC, Bayer AJ, Fish M, Pickering J, Mitchell C, Gallacher JE. Sleep disturbance and daytime sleepiness predict vascular dementia. J Epidemiol Community Health. 2011;65(9):820-824.
10. Keage HA, Banks S, Yang KL, Morgan K, Brayne C, Matthews FE. What sleep characteristics predict cognitive decline in the elderly? Sleep Med. 2012; 13(7):886-892.
11. MerlinoG, PianiA, GigliGL, etal.Daytimesleepiness isassociatedwithdementiaandcognitivedeclineinolder Italian adults: A population-based study. Sleep Med. 2010;11(4):372-377.
12. Hayley AC, Williams LJ, Kennedy GA, et al. Excessive daytime sleepiness and falls among older men and women: cross-sectional examination of a population-based sample. BMC Geriatr. 2015;15:74.
13. CarvalhoDZ, StLouis EK, BoeveBF, et al.Excessive daytimesleepinessandfatiguemayindicateaccelerated brain aging in cognitively normal late middle-Aged and older adults. Sleep Med. 2017;32:236-243.
14. Ju YE, Lucey BP, Holtzman DM. Sleep and Alzheimer disease pathology: A bidirectional relationship. Nat Rev Neurol. 2014;10(2):115-119.
15. Cedernaes J, Osorio RS, Varga AW, Kam K, Schih HB, Benedict C. Candidate mechanisms underlying the association between sleep-wake disruptions and Alzheimers disease. Sleep Med Rev. 2017;31:102-111.
16. Xie L, Kang H, XuQ, et al. Sleep drivesmetabolite clearance from the adult brain. Science. 2013;342 (6156):373-377.
17. Kang JE, LimMM, Bateman RJ, et al.Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle. Science. 2009;326(5955):1005-1007.
18. Varga AW, Wohlleber ME, Gimez S, et al. Reduced slow-wave sleep is associated with high cerebrospinal fluid Aβ42 levels in cognitively normal elderly. Sleep. 2016;39(11):2041-2048.
19. SpiraAP, GamaldoAA, AnY, etal.Self-reportedsleep andβ-Amyloid deposition incommunity-dwellingolder adults. JAMANeurol. 2013;70(12):1537-1543.
20. Sprecher KE, Bendlin BB, Racine AM, et al. Amyloid burden is associated with self-reported sleep in nondemented late middle-Aged adults. Neurobiol Aging. 2015;36(9):2568-2576.
21. Ju YE, McLeland JS, Toedebusch CD, et al. Sleep quality and preclinical Alzheimer disease. JAMA Neurol. 2013;70(5):587-593.
22. Roh JH, Huang Y, Bero AW, et al. Disruption of the sleep-wake cycle and diurnal fluctuation of β-Amyloid in mice with Alzheimers disease pathology. Sci Transl Med. 2012;4(150):150ra122.
23. Mander BA, Marks SM, Vogel JW, et al. β-Amyloid disrupts human NREM slow waves and related hippocampus-dependent memory consolidation. Nat Neurosci. 2015;18(7):1051-1057.
24. Cirrito JR, Yamada KA, Finn MB, et al. Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. Neuron. 2005;48(6):913-922.
25. Kamenetz F, Tomita T, Hsieh H, et al. APP processing and synaptic function. Neuron. 2003;37 (6):925-937.
26. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimers disease: progress and problems on the road to therapeutics. Science. 2002;297(5580): 353-356.
27. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82(4):239-259.
28. Hardy JA, Higgins GA. Alzheimers disease: The amyloid cascade hypothesis. Science. 1992;256 (5054):184-185.
29. JackCRJr, KnopmanDS, JagustWJ, et al. Tracking pathophysiological processes in Alzheimers disease: Anupdatedhypotheticalmodelofdynamicbiomarkers. Lancet Neurol. 2013;12(2):207-216.
30. Bilgel M, Prince JL, Wong DF, Resnick SM, Jedynak BM. A multivariate nonlinear mixed effects model for longitudinal image analysis: Application to amyloid imaging. Neuroimage. 2016;134:658-670.
31. RobertsRO, GedaYE, KnopmanDS, et al.TheMayo ClinicStudyofAging:designandsampling, participation, baseline measures and sample characteristics. Neuroepidemiology. 2008;30(1):58-69.
32. Petersen RC, Roberts RO, Knopman DS, et al; TheMayo Clinic Study of Aging. Prevalence of mild cognitive impairment is higher in men. Neurology. 2010;75(10):889-897.
33. Roberts RO, Geda YE, Knopman DS, et al. The incidence of MCI differs by subtype and is higher in men: The Mayo Clinic Study of Aging. Neurology. 2012;78(5):342-351.
34. BoeveBF, MolanoJR, FermanTJ, etal.Validationof theMayo SleepQuestionnaire to screen forREMsleep behavior disorder in a community-based sample. J Clin Sleep Med. 2013;9(5):475-480.
35. JohnsMW. A new method for measuring daytime sleepiness: The Epworth Sleepiness Scale. Sleep. 1991;14(6):540-545.
36. Sforza E, Pichot V, Martin MS, Barthy JC, Roche F. Prevalence and determinants of subjective sleepiness in healthy elderly with unrecognized obstructive sleep apnea. Sleep Med. 2015;16(8): 981-986.
37. RoccaWA, Yawn BP, St Sauver JL, Grossardt BR, Melton LJ III. History of the Rochester Epidemiology Project: half a century of medical records linkage in a US population. Mayo Clin Proc. 2012;87(12):1202-1213.
38. St Sauver JL, Grossardt BR, Yawn BP, et al. Data resource profile: The Rochester Epidemiology Project (REP) medical records-linkage system. Int J Epidemiol. 2012;41(6):1614-1624.
39. VemuriP, LesnickTG, PrzybelskiSA, et al.Effect of lifestyle activitiesonAlzheimerdiseasebiomarkersand cognition. Ann Neurol. 2012;72(5):730-738.
40. Beck AT, Steer RA, Ball R, Ranieri W. Comparisonof Beck Depression Inventories-IA and-II in psychiatric outpatients. J Pers Assess. 1996;67(3):588-597.
41. Senjem ML, Gunter JL, Shiung MM, Petersen RC, Jack CR Jr. Comparison of different methodological implementations of voxel-based morphometry in neurodegenerative disease. Neuroimage. 2005;26(2):600-608.
42. Jack CR Jr, Lowe VJ, Senjem ML, et al. 11C PiB and structural MRI provide complementary information in imaging of Alzheimers disease and amnestic mild cognitive impairment. Brain. 2008; 131(pt 3):665-680.
43. Jack CR Jr, Wiste HJ, Vemuri P, et al; Alzheimers Disease Neuroimaging Initiative. Brain beta-Amyloid measures andmagnetic resonance imaging atrophy both predict time-To-progression from mild cognitive impairment to Alzheimers disease. Brain. 2010;133(11): 3336-3348.
44. Jack CR Jr, Wiste HJ, Lesnick TG, et al. Brain β-Amyloid load approaches a plateau. Neurology. 2013;80(10):890-896.
45. Murray ME, Lowe VJ, Graff-Radford NR, et al. Clinicopathologic and 11C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimers disease spectrum. Brain. 2015;138(pt 5):1370-1381.
46. Mundry R, Nunn CL. Stepwise model fitting and statistical inference: Turning noise into signal pollution. Am Nat. 2009;173(1):119-123.
47. Brettschneider J, Del Tredici K, Lee VM, Trojanowski JQ. Spreading of pathology in neurodegenerative diseases: A focus on human studies. Nat Rev Neurosci. 2015;16(2):109-120.
48. Pack AI, Dinges DF, Gehrman PR, Staley B, Pack FM, Maislin G. Risk factors for excessive sleepiness in older adults. Ann Neurol. 2006;59(6): 893-904.
49. Spira AP, Yager C, Brandt J, et al. Objectively measured sleep and β-Amyloid burden in older adults: A pilot study. SAGE Open Med. 2014;2: 2050312114546520.
50. Osorio RS, Ayappa I, Mantua J, et al. Interaction betweensleep-disorderedbreathingandapolipoprotein E genotype on cerebrospinal fluid biomarkers for Alzheimers disease in cognitively normal elderly individuals. Neurobiol Aging. 2014;35(6):1318-1324.
51. Liguori C, Mercuri NB, Izzi F, et al. Obstructive sleep apnea is associated with early but possibly modifiable Alzheimers disease biomarkers changes. Sleep. 2017;40(5):zsx011.
52. Shiota S, Takekawa H, Matsumoto SE, et al. Chronic intermittent hypoxia/reoxygenation facilitate amyloid-β generation in mice. J Alzheimers Dis. 2013;37(2):325-333.
53. Gelber RP, Redline S, Ross GW, et al. Associations of brainlesionsatautopsywithpolysomnographyfeatures before death. Neurology. 2015;84(3):296-303.
54. Gooneratne NS, VitielloMV. Sleep in older adults: normative changes, sleep disorders, and treatment options. Clin Geriatr Med. 2014;30(3):591-627.
55. Guilleminault C, Partinen M, Quera-Salva MA, Hayes B, Dement WC, Nino-Murcia G. Determinants of daytime sleepiness in obstructive sleep apnea. Chest. 1988;94(1):32-37.
56. Seneviratne U, Puvanendran K. Excessive daytime sleepiness in obstructive sleep apnea: prevalence, severity, and predictors. Sleep Med. 2004;5(4):339-343.
57. Bennett LS, Langford BA, Stradling JR, Davies RJ. Sleep fragmentation indices as predictors of daytime sleepiness and nCPAP response in obstructive sleep apnea. Am J Respir Crit Care Med. 1998;158(3):778-786.
58. Punjabi NM, Bandeen-Roche K, Marx JJ, Neubauer DN, Smith PL, Schwartz AR. The association between daytime sleepiness and sleep-disordered breathing in NREM and REM sleep. Sleep. 2002;25(3):307-314.
59. Punjabi NM, Ohearn DJ, Neubauer DN, et al. Modeling hypersomnolence in sleep-disordered breathing: A novel approach using survival analysis. Am J Respir Crit Care Med. 1999;159(6):1703-1709.
60. Heinzer R, Gaudreau H, Dary A, et al. Slow-wave activity in sleep apnea patients before and after continuous positive airway pressure treatment: contribution to daytime sleepiness. Chest. 2001;119(6):1807-1813.
61. Murphy M, Riedner BA, Huber R, Massimini M, Ferrarelli F, Tononi G. Sourcemodelingsleepslowwaves. Proc Natl Acad SciUSA. 2009;106(5):1608-1613.
62. Lucey BP, Mawuenyega KG, Patterson BW, et al. Associations between β-Amyloid kinetics and the β-Amyloid diurnal pattern in the central nervous system. JAMA Neurol. 2017;74(2):207-215.
63. Bero AW, Yan P, Roh JH, et al. Neuronal activity regulates the regional vulnerability to amyloid-β deposition. Nat Neurosci. 2011;14(6):750-756.
64. Vyazovskiy VV, Cirelli C, Pfister-Genskow M, Faraguna U, Tononi G. Molecular and electrophysiological evidence for net synaptic potentiation in wake and depression in sleep. Nat Neurosci. 2008;11(2):200-208.
65. Wisor JP, Rempe MJ, Schmidt MA, Moore ME, Clegern WC. Sleep slow-wave activity regulates cerebral glycolytic metabolism. Cereb Cortex. 2013; 23(8):1978-1987.
66. Donlea JM, Ramanan N, Shaw PJ. Use-dependent plasticity in clock neurons regulates sleep need in Drosophila. Science. 2009;324(5923):105-108.
67. Tononi G, Cirelli C. Sleepandsynaptichomeostasis: A hypothesis. Brain Res Bull. 2003;62(2):143-150.
68. Tabuchi M, Lone SR, Liu S, et al. Sleep interacts with Aβ to modulate intrinsic neuronal excitability. Curr Biol. 2015;25(6):702-712.
69. Kam K, Duffy AM, Moretto J, LaFrancois JJ, Scharfman HE. Interictal spikes during sleep are an early defect in the Tg2576 mouse model of β-Amyloid neuropathology. Sci Rep. 2016;6:20119.
70. Nofzinger EA, Buysse DJ, Miewald JM, et al. Human regional cerebral glucose metabolism during non-rapid eyemovement sleep in relation to waking. Brain. 2002;125(pt 5):1105-1115.
71. Vlassenko AG, Vaishnavi SN, Couture L, et al. Spatial correlation between brain aerobic glycolysis and amyloid-β (Aβ) deposition. Proc Natl Acad Sci U S A. 2010;107(41):17763-17767.
72. Raichle ME, MacLeod AM, Snyder AZ, Powers WJ, Gusnard DA, Shulman GL. Adefaultmodeof brain function. Proc Natl Acad SciUSA. 2001;98(2):676-682.
73. Horovitz SG, Braun AR, Carr WS, et al. Decoupling of the brains default mode network during deep sleep. Proc Natl Acad Sci U S A. 2009; 106(27):11376-11381.
74. Sann PG, Wehrle R, Hoehn D, et al. Development of the brains default mode network from wakefulness to slow wave sleep. Cereb Cortex. 2011;21(9):2082-2093.
75. Chen X, Guo C, Kong J. Oxidative stress in neurodegenerative diseases. Neural Regen Res. 2012;7(5):376-385.
76. Mattson MP, Magnus T. Ageing and neuronal vulnerability. Nat Rev Neurosci. 2006;7(4):278-294.
77. Theofilas P, Ehrenberg AJ, Dunlop S, et al. Locus coeruleus volume and cell population changes during Alzheimers disease progression: A stereological study in human postmortem brains with potential implication for early-stage biomarker discovery. Alzheimers Dement. 2017;13(3):236-246.
78. Grothe M, Heinsen H, Teipel SJ. Atrophy of the cholinergic basal forebrain over the adult age range and in early stages of Alzheimers disease. Biol Psychiatry. 2012;71(9):805-813.
79. Schliebs R. Basal forebrain cholinergic dysfunction in Alzheimers disease: interrelationship with beta-Amyloid, inflammationandneurotrophinsignaling. Neurochem Res. 2005;30(6-7):895-908.
80. Ross JA, McGonigle P, Van Bockstaele EJ. Locus coeruleus, norepinephrine and Aβ peptides in Alzheimers disease. Neurobiol Stress. 2015;2:73-84.
81. Liguori C, Romigi A, Nuccetelli M, et al. Orexinergic system dysregulation, sleep impairment, and cognitive decline in Alzheimer disease. JAMA Neurol. 2014;71(12):1498-1505.
82. Slats D, Claassen JA, Lammers GJ, Melis RJ, Verbeek MM, Overeem S. Association between hypocretin-1 and amyloid-β42 cerebrospinal fluid levels in Alzheimers disease and healthy controls. Curr Alzheimer Res. 2012;9(10):1119-1125.
83. Swaab DF, Fliers E, Partiman TS. The suprachiasmatic nucleus of the human brain in relation to sex, age and senile dementia. Brain Res. 1985;342(1):37-44.
84. Theofilas P, Dunlop S, Heinsen H, Grinberg LT. Turning on the light within: subcortical nuclei of the isodentritic core and their role in Alzheimers disease pathogenesis. J Alzheimers Dis. 2015;46(1):17-34.
85. Karageorgiou E, Vossel KA. Brain rhythm attractor breakdown in Alzheimers disease: functional and pathologic implications. Alzheimers Dement. 2017;13(9):1054-1067.
86. Zhu Y, Fenik P, Zhan G, Xin R, Veasey SC. Degeneration in arousal neurons in chronic sleep disruption modeling sleep apnea. Front Neurol. 2015;6:109.
87. Zhao ZZY, Zhao X, Zhan G, Fenik P, Veasey S. Chronic short sleep initiates an amyloid cascade in locus coeruleus neurons and tau-dependent neurodegeration. Sleep (Basel). 2017;40(suppl):A100.
88. Kendzerska TB, Smith PM, Brignardello-Petersen R, Leung RS, Tomlinson GA. Evaluationofthemeasurement propertiesoftheEpworthSleepinessScale:asystematic review. Sleep Med Rev. 2014;18(4):321-331.
89. Onen F, Moreau T, Gooneratne NS, Petit C, Falissard B, Onen SH. Limits of the Epworth Sleepiness Scale in older adults. Sleep Breath. 2013; 17(1):343-350.
90. Johns MW. Sleepiness in different situations measured by the Epworth Sleepiness Scale. Sleep. 1994;17(8):703-710.
91. Bonnet MH. ACNS clinical controversy: MSLT andMWT have limited clinical utility. J Clin Neurophysiol. 2006;23(1):50-58.
92. Trotti LM, Staab BA, Rye DB. Test-retest reliability of the multiple sleep latency test in narcolepsy without cataplexy and idiopathic hypersomnia. J Clin Sleep Med. 2013;9(8):789-795.
93. Brown BM, Rainey-Smith SR, Villemagne VL, et al; AIBL Research Group. The relationship between sleep quality and brain amyloid burden. Sleep. 2016;39(5):1063-1068.